Venrock Associates VII, L.P. - Jun 22, 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role: 10%+ Owner
Signature: /s/ David L. Stepp, Authorized Signatory
Stock symbol: CYT
Transactions as of: Jun 22, 2021
Transactions value $: $0
Form type: 4
Date filed: 6/23/2021, 04:08 PM
Previous filing: Jun 17, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYT	Common Stock	Conversion of derivative security		+3.26M			3.26M	Jun 22, 2021	By Funds	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYT	Series B Convertible Preferred Stock	Conversion of derivative security		-10M	-100%		0	Jun 22, 2021	Common Stock	2.93M		Direct	F1
transaction	CYT	Series C Convertible Preferred Stock	Conversion of derivative security		-1.11M	-100%		0	Jun 22, 2021	Common Stock	325K		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Venrock Associates VII, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date.
F2	Consists of 3,009,710 shares of Common Stock held by Venrock Associates VII, L.P. ("VA VII") and 249,315 shares of Common Stock held by Venrock Partners VII, L.P. ("VP VII"). Venrock Management VII, LLC ("VM VII") is the sole general partner of VA VII and VP VII and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA VII and VP VII except to the extent of its indirect pecuniary interest therein.

Content

Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 1:3.4088 upon completion of the Issuer's initial public offering. The shares have no expiration date.

Consists of 3,009,710 shares of Common Stock held by Venrock Associates VII, L.P. ("VA VII") and 249,315 shares of Common Stock held by Venrock Partners VII, L.P. ("VP VII"). Venrock Management VII, LLC ("VM VII") is the sole general partner of VA VII and VP VII and may be deemed to beneficially own these shares and expressly disclaims beneficial ownership over all shares held by VA VII and VP VII except to the extent of its indirect pecuniary interest therein.